Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 1/2009

01-01-2009 | Original Research Article

Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-—O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

Authors: Dr Rosie Z. Yu, Richard S. Geary, Jo Ann D. Flaim, Gina C. Riley, Diane L. Tribble, André A. vanVliet, Mark K. Wedel

Published in: Clinical Pharmacokinetics | Issue 1/2009

Login to get access

Abstract

Background and objectives

Mipomersen sodium (ISIS 301012) is a 20-mer phosphorothioate antisense oligonucleotide that is complementary to human apolipoprotein B-100 (apoB-100) messenger RNA and subsequently reduces translation of ApoB-100 protein, the major apolipoprotein of very low-density lipoprotein, intermediate-density lipoprotein and low-density lipoprotein (LDL). Mipomersen sodium is currently being studied in phase II/III clinical studies to determine its clinical utility as add-on therapy to HMG-CoA reductase inhibitors or other lipid-lowering agents in subjects with hypercholesterolaemia. The aim of this study was to characterize the pharmacokinetic interactions of mipomersen sodium with simvastatin and ezetimibe. Another aim was to evaluate the ability of mipomersen sodium to inhibit major cytochrome P450 (CYP) isoenzymes in vitro.

Methods

In a phase I clinical study, ten healthy subjects per cohort received a single oral dose of simvastatin 40 mg or ezetimibe 10 mg followed by four 2-hour intravenous doses of mipomersen sodium 200 mg over an 8-day period, with simvastatin 40 mg or ezetimibe 10 mg being administered again with the last dose of mipomersen sodium. Mipomersen sodium pharmacokinetic profiles were assessed following the first dose (mipomersen sodium alone) and the last dose (mipomersen sodium in combination with simvastatin or ezetimibe). Plasma samples for measurement of simvastatin, simvastatin acid, and free and total ezetimibe concentrations were collected at various timepoints following their first and last oral dosing. A comparative pharmacokinetic analysis was performed to determine if there were any effects resulting from coadministration of mipomersen sodium with these lipid-lowering drugs. In addition to the clinical pharmacokinetic analysis, the ability of mipomersen sodium to inhibit the major CYP isoform enzymes (namely CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) was evaluated in cryo-preserved human hepatocytes in vitro.

Results

The area under the plasma concentration-time curve (AUC) from 0 to 24 hours (AUC24), maximum plasma concentration and apparent elimination half-life values of mipomersen sodium were similar when administered alone and in combination with oral simvastatin or oral ezetimibe. The 90% confidence intervals of the geometric least squares means ratios (%Reference) of the mipomersen sodium AUC24 values were 93.6, 107 when administered together with simvastatin, and 92.4, 111 when administered with ezetimibe. Therefore, there were no large deviations outside the default no-effect boundaries (80–125%) for total exposure (the AUC) of mipomersen sodium in combination with either simvastatin or ezetimibe. Similarly, large deviations outside the default no-effect boundaries were not observed for simvastatin, simvastatin acid, or free and total ezetimibe exposure in combination with mipomersen sodium. In cryo-preserved human hepatocytes, mipomersen sodium exhibited no cytotoxicity. Significant cell uptake was demonstrated by analysing cell-associated concentrations of mipomersen sodium. All evaluated enzyme activities had <10% inhibition at tested concentrations up to 800 μg/mL (∼100 μmol/L) of mipomersen sodium, and dose-dependent inhibition was not observed. Therefore, mipomersen sodium is not considered an inhibitor of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 enzyme activities.

Conclusions

These data provide evidence that mipomersen sodium exhibits no clinically relevant pharmacokinetic interactions with the disposition and clearance of simvastatin or ezetimibe, and vice versa. Moreover, mipomersen sodium does not inhibit any of the major CYP enzymes that were evaluated. Taken together, the results from this study support the use of mipomersen sodium in combination with oral lipid-lowering agents.
Literature
1.
Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114(16): 1729–35PubMedCrossRef
2.
Kastelein J, Akdim F, Trip M. ISIS 301012, an antisense inhibitor of apolipoprotein B, produces significant additional reduction of low-density lipoprotein cholesterol and apolipoprotein B in hypercholesterolemic subjects on statins not meeting target [abstract no. 820-7]. J Am Coll Cardiol 2007, 49 (9 Suppl. A) 393A
3.
Stein E, Wedel M, Bradley J. Statin-like, dose-dependent reductions in LDL cholesterol and apolipoprotein B with ISIS 301012, an antisense inhibitor of apolipoprotein B, in subjects with polygenic hypercholesterolemia [abstract no. 1206-278]. J Am Coll Cardiol 2007; 49 (9 Suppl. A): 333A
4.
Stein E. High low-density lipoprotein cholesterol on three drugs [abstract no. 603-8]. Common Challenges in Preventive Cardiology Symposium, 56th Scientific Session of the American College of Cardiology; 2007 Mar 24–27; New Orleans (LA)
5.
Yu RZ, Kim T-W, Hong A, et al. Cross-species pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012, targeting human apoB-100. Drug Metab Dispos 2007; 35: 460–8PubMedCrossRef
6.
Geary RS, Ushiro-Watanabe T, Truong L, et al. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 2001; 296(3): 890–7PubMed
7.
Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factoralpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003; 31(11): 1419–28PubMedCrossRef
8.
Yu RZ, Geary RS, Monteith DK, et al. Tissue disposition of a 2′-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharmaceutical Sci 2004; 93: 48–59CrossRef
9.
Gaus HJ, Owens SR, Winniman M, et al. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem 1997; 69(3): 313–9PubMedCrossRef
10.
Phillips JA, Craig SJ, Bayley D, et al. Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 1997; 54(6): 657–68PubMedCrossRef
11.
Grundy JS, Yu RZ, Geary RS, et al. Comparative single-dose disposition of radiolabeled ISIS 104838 and ISIS 113715 in rat. Annual Meeting of Pharmaceutical Scientists; 2002 Nov 10–14; Toronto
12.
Data on file, Isis Pharmaceuticals, Inc., 2007
13.
Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004; 44(9): 1054–62PubMedCrossRef
14.
Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44(5): 467–94PubMedCrossRef
15.
16.
Yu RZ, Baer B, Chappel A, et al. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 2002; 304(1): 19–25PubMedCrossRef
17.
Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm Res 2000; 17(12): 1551–7PubMedCrossRef
18.
19.
Sewell LK, Geary RS, Baker BF, et al. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 2002; 303(3): 1334–43PubMedCrossRef
20.
21.
US FDA Center for Drug Evaluation and Research. Guidance for industry: in vivo drug metabolism/drug interaction studies: study design, data analysis, and recommendations for dosing and labeling, Rockville (MD): US FDA, 1999 [online]. Available from URL: http://​www.​fda.​gov/​CbER/​gdlns/​metabol.​htm [Accessed 2008 Oct 15]
22.
Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clinical Pharmacol Ther 1998; 64(2): 177–82CrossRef
23.
Lilja JJ, Kivisto KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 2000; 68(4): 384–90PubMedCrossRef
24.
Lohitnavy M, Lohitnavy O, Chaijittiprasert K, et al. Bioequivalence study of two formulations of simvastatin tablets in healthy Thai volunteers. Arzneimittelforschung 2004; 54(1): 31–4PubMed
25.
Zetia® (ezetimibe) tablets [package insert]. North Wales (PA): Merck/Schering-Plough Pharmaceuticals, 2001, 2002
26.
Reyderman L, Kosoglou T, Statkevich P, et al. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Int J Clin Pharmacol Ther 2004; 42(9): 512–8PubMed
27.
Kedderis GL, Held SD. Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactive and hepatic dosimetry in rats, mice, and humans. Toxicol Appl Pharmacol 1996; 140: 124–30PubMedCrossRef
28.
Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006; 259(3): 247–58PubMedCrossRef
29.
Watanabe TA, Geary RS, Riley-McMullen GC, et al. In vitro protein binding evaluation of an antisense oligonucleotide, mipomersen, targeting human apolipoprotein B-100. National Biotechnology Conference, American Association of Pharmaceutical Scientists; 2008 Jun 22–25; Toronto
30.
Geary RS, Bradley JD, Watanabe T, et al. Lack of pharmacokinetic interaction for ISIS 113715, a 2′-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet 2006; 45(8): 789–801PubMedCrossRef
31.
Adjei AA, Dy GK, Erlichman C, et al. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 2003; 9(1): 115–23PubMed
32.
Villalona-Calero MA, Ritch P, Figueroa JA, et al. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004; 10 (18 Pt 1): 6086–93PubMedCrossRef
33.
Motl SE. LY900003: a novel compound for the treatment of non-small cell lung cancer. Cancer Ther 2003; 1: 237–44
34.
Geary RS, Leeds JM, Fitchett J, et al. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos 1997; 25(11): 1272–81PubMed
35.
Yu RZ, Geary RS, Leeds JM, et al. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 2001; 90(2): 182–93PubMedCrossRef
36.
Glover JM, Leeds JM, Mant TG, et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 1997; 282(3): 1173–80PubMed
37.
Brown DA, Kang SH, Gryaznov SM, et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994; 269(43): 26801–5PubMed
38.
Watanabe TA, Geary RS, Levin AA. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 2006; 16(2): 169–80PubMedCrossRef
Metadata
Title
Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-—O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
Authors
Dr Rosie Z. Yu
Richard S. Geary
Jo Ann D. Flaim
Gina C. Riley
Diane L. Tribble
André A. vanVliet
Mark K. Wedel
Publication date
01-01-2009
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 1/2009
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/0003088-200948010-00003

Other articles of this Issue 1/2009

Clinical Pharmacokinetics 1/2009 Go to the issue

Original Research Article

Steady-State Concentrations of Mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and their Enantiomers in Relation to Cytochrome P450 2D6 Genotype, Age and Smoking Behaviour

Original Research Article

Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects

Review Article

Ketolides — The Modern Relatives of Macrolides

Review Article

Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development